fda warning bpc-157 status 2024 2025 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: FDA's April 2026
Description
Both BPC-157 and TB-500 are research chemicals intended for laboratory and preclinical investigation only, and neither is approved by the FDA or any major regulatory agency
Patients should keep the area clean and follow proper hygiene practices to minimize this risk
This makes it ideal for use in multi-dose vials, allowing for repeated withdrawals without the risk of contamination
TLDR: Bryan Johnsons Peptide Plan The Framework First: He treats every peptide as a closed loop
